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Abstract 
Background: Growth differentiation factor 15 (GDF‑15) is a member of the transforming growth factor ß family and 
has been associated with inflammation, cancer, aging, diabetes mellitus (DM) and atherosclerosis. Determinants of 
GDF‑15 have been investigated in several conditions. We aimed to investigate determinants of GDF‑15 plasma levels 
in patients with angiographically proven coronary artery disease (CAD).
Methods: Four hundred and seventy three consecutive patients with CAD were investigated between May 2009 
and February 2011. Patients were separated into those with stable CAD (SCAD) and with ST‑elevation and non‑ST‑ele‑
vation myocardial infarction (STEMI and NSTEMI). Blood samples for determination of GDF‑15 were obtained before 
coronary angiography. Determinant of GDF‑15 levels were analyzed by logistic regression analysis in unadjusted and 
adjusted models. Study endpoints were cardiovascular death (CV‑death), myocardial infarction, unstable angina, 
unplanned revascularization, stent thrombosis and stroke assessed at a mean follow‑up of 188 (177.2–243) days.
Results: Overall median and (25–27th percentile) GDF‑15 level was 1212.8 pg/ml (833.2–1957 pg/ml). GDF‑15 was 
significantly higher in STEMI compared to SCAD and NSTEMI groups (P < 0.0001). In a multivariate regression analysis 
advanced age, DM, acute hyperglycemia (AHG), CRP and chronic kidney disease (CKD) were independent predictors 
of elevated GDF‑15 levels (P < 0.05). Receiver operating curve analysis of GDF‑15 for prediction of CV‑death showed 
an area under the curve of 0.852 with a confidence interval of 0.745‑0.960, P < 0.0001. The estimated cut‑off was 
2094.6 pg/ml with a sensitivity of 76 % and specificity of 80 %.
Conclusion: In patients with CAD undergoing PCI with stent implantation, GDF‑15 is determined by advanced age, 
acute and chronic hyperglycemia, inflammation and CKD. GDF‑15 is a valuable predictor of CV‑death in a population 
of CAD patients after PCI.
Keywords: Growth differentiation factor 15, Acute coronary syndrome, Coronary artery disease, Diabetes mellitus, 
Acute hyperglycemia
© 2016 Farhan et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Growth differentiation factor 15 (GDF-15) is a member 
of the transforming growth factor family [1]. GDF-15 
has been described in various conditions [2–4]. GDF-15 
has been introduced as a prognostic marker for patients 
with coronary artery disease (CAD) especially in the 
case of acute non-ST-elevation myocardial infarction 
(NSTEMI) [5–7]. Additionally GDF-15 has been linked 
to hyperglycemia and diabetes mellitus (DM) [4, 8]. 
GDF-15 was investigated also as a predictor of future 
insulin resistance and impaired glucose control in obese 
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non-diabetic subjects [9]. Furthermore, GDF-15 was 
linked to impaired fasting glucose [8]. Additionally GDF-
15 predicted worsening albuminuria in patients with DM 
[3].
Few data are available on determinants of GDF-15 in 
patients with CAD. Therefore we aimed to investigate 
GDF-15 in patients with CAD undergoing percutaneous 
coronary intervention (PCI) with stent implantation.
Methods
In total 473 consecutive patients from the WIlhelminen 
hospital Monitoring of Antiplatelet Activity (WILMAA)-
registry between May 2009 and February 2011 were 
included in this prospective observational investiga-
tion [10]. Briefly, consecutive patients, with percutanous 
coronary intervention (PCI) and coronary stenting due 
to stable coronary artery disease (SCAD) with positive 
ischemia testing (treadmill examination, dobutamine 
stress echocardiography or single-photon-emission com-
puted tomography) or acute coronary syndrome (ACS), 
aged >18 years were eligible for inclusion in the present 
study. ACS was diagnosed according to the guidelines 
of the European Society of Cardiology (ESC) [11, 12]. 
Implantation of drug eluting or bare metal stents, and 
the use of accompanying antithrombotic regimens were 
based on the decision of the treating interventionist. The 
city of Vienna ethic committee approved the study and all 
patients gave their informed consent.
Patients were divided according their presentation into 
those with SCAD as well as ST-elevation myocardial 
infarction (STEMI) or NSTEMI.
Definitions Acute hyperglycemia (AHG) was defined as 
glucose concentration of ≥140 mg/dl in absence of DM 
in patients admitted with ACS [13], chronic kidney dis-
ease (CKD) was defined as an estimated glomerular fil-
tration rate (eGFR) of <60 ml/min at admission [14]. DM 
was defined as history of elevated glucose concentra-
tions treated by dietary control or using glucose-lower-
ing drugs. History of congestive heart failure (CHF) was 
defined according to the European society of cardiology 
guidelines (ESC) [15].
Endpoint definition
According the recommendation of the Academic 
Research Consortium regarding stent trials [16], the fol-
lowing endpoints were investigated: (1) cardiovascular 
death according to the TIMI-definition (http://www.timi.
org), as well as any death that could not be attributed 
to non-cardiovascular reasons (2) nonfatal myocardial 
infarction according to the TIMI-definition (http://www.
timi.org) as well as (3) any unplanned revascularization. 
Additionally (4) definite and probable stent thrombo-
sis (ST) according to the academic research consortium 
definition [16], (5) unstable angina defined as ischemic 
symptoms without elevation of troponin I above the 
upper limit of normal and (6) transient ischemic attack 
(TIA) [17] or stroke, defined as cerebral infarction were 
recorded. Data were collected prospectively and entered 
into a database. Follow-up information was obtained by 
contacting patients after 6 months (±2 months). Source 
documents of all possible events were collected.
Laboratory parameters
Blood samples for glucose, high sensitive C-reactive 
protein (CRP) and creatinine were obtained at hospital 
admission and high- and low-density lipoprotein (HDL 
and LDL) cholesterol and triglycerides were collected at 
the first day after admission in fasting condition. A cer-
tified clinical laboratory at our hospital performed the 
measurement of that laboratory parameter. Blood sam-
ples for GDF-15 were collected before coronary angi-
ography. Blood samples for detection of GDF-15 were 
centrifuged immediately after collection and were stored 
at −80  °C until measurement. GDF-15 plasma concen-
trations were measured using a quantitative sandwich 
ELISA kit (Quantikine ELISA, R&D Systems) with inter- 
and intra-assay CVs of <6 and 2.8 %, respectively.
Statistical analysis
Continuous data are expressed as proportions and con-
tinuous data as mean  ±  standard error of the mean. 
Categorical variables were compared by Chi square test, 
while analysis of variance (ANOVA) for continuous 
variables. Determinates of GDF-15 levels were tested 
using a univariate binary logistic regression analysis. All 
variables, which were tested significant in the univari-
ate model, were inserted in a multivariate binary logis-
tic regression model with inclusion method. Results of 
binary logistic regression analysis were presented as odds 
ratio (OR) and 95  % confidence interval (CI). Receiver 
operating characteristic (ROC) analysis was performed 
to determine whether GDF-15 plasma levels predict 
death and ischemic endpoints. All statistical tests were 
2-sided and statistical significance was accepted if the p 
value was  <0.05. All statistical analyses were performed 
using Software Package Social Sciences (IBM, SPSS).
Results
The median (25–27th percentile) of GDF-15 levels was 
1212.8  pg/ml (833.2–1957  pg/ml) in our study popu-
lation. Patient’s demographic and clinical presenta-
tion data are depicted in Table  1. Patients with STEMI 
were significantly more smokers than those with SCAD 
and NSTEMI patients. On the other side patients with 
SCAD had higher cardiovascular risk profile in terms 
of significantly higher rates of hyperlipidemia, lower 
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HDL-cholesterol and previous myocardial infarction 
(Table 1).
Additionally patients with SCAD were trend-wise older 
than those with ACS (STEMI and NSTEMI patients). 
Patients with STEMI had significantly more hospitaliza-
tion days compared to those with SCAD and NSTEMI 
(Table 1). GDF-15 plasma levels were significantly higher 
in patients with STEMI compared to SCAD and NSTEMI 
groups (Fig.  1; Table  1). Patients with ACS (STEMI and 
NSTEMI together) showed significant higher proportion 
of GDF-15 plasma levels above 1800  pg/ml than those 
with SCAD (68.3 vs. 31.7 % respectively, P = 0.037). Those 
patients with GDF-15 plasma levels >1800 pg/ml showed 
higher CV-death rates compared with those patients with 
GDF-15 <1200 and 1200–1800 pg/ml (Fig. 2). 
Determinants of elevated GDF‑15
In univariate analysis advanced age (age  >75  years), 
ACS on presentation, history of myocardial infarction 
(MI), current smoking status, elevated BMI (>25  kg/
m2), AHG in those patients with ACS, DM, CKD, CRP 
and NYHA ≥2 were significant determinants of elevated 
GDF-15 plasma levels (Table 2). In a multivariate analysis 
advanced age, DM, AHG, CRP and CKD were independ-
ent predictors of elevated GDF-15 levels (Table 2; Fig. 3). 
ROC analysis of GDF‑15 plasma levels
GDF-15 was a precise predictor of cardiovascular mor-
tality according to the ROC Analysis [area under the 
curve (AUC) 0.852, CI 0.745–0.960, P < 0.0001] (Fig. 4). 
The best cut-off was 2094.67 pg/ml with a sensitivity of 
76 % and specificity of 80 % (Fig. 4).
Table 1 Baseline and demographic parameters
DM diabetes mellitus, CAD coronary artery disease, CKD chronic kidney disease, GDF-15 growth differentiation factor 15, BMI body mass index, e-GFR estimated 
glomerular filtration rate, CRP high sensitive C-reactive protein, HDL high-density lipoprotein, LDL low-density lipoprotein
Variable SCAD (n = 189) STEMI (n = 121) NSTEMI (n = 163) P value
Age 65.2 ± 0.786 61.9 ± 1.34 64.9 ± 1.05 0.067
Age >75 (%) 41 (21.7) 29 (24) 45 (27.6) 0.433
Female gender (%) 55 (29.1) 41 (33.9) 54 (33.1) 0.60
Hypertension (%) 170 (90) 98 (81) 139 (85.3) 0.058
Hyperlipidemia (%) 160 (85.1) 83 (68.6) 129 (79.1) 0.002
Current smoking (%) 39 (20.6) 44 (36.4) 52 (31.9) 0.006
DM (%) 58 (30.9) 28 (23.1) 50 (30.7) 0.27
Family history of CAD (%) 77 (41) 45 (37.2) 62 (38) 0.766
Previous MI (%) 63 (33.5) 19 (15.7) 42 (25.8) 0.002
CKD (%) 33 (17.5) 19 (15.7) 30 (18.4) 0.83
GDF‑15 pg/ml 1421.1 ± 74.9 2189.2 ± 206.7 1695 ± 114.8 <0.0001
BMI (Kg/m2) 28.51 ± 0.35 28 ± 0.43 27.97 ± 0.35 0.499
e‑GFR (ml/min) 65.27 ± 0.71 63.65 ± 1.04 63.57 ± 1.03 0.31
CRP (mg/dl) 7.83 ± 2.28 17.42 ± 3.88 11.05 ± 2.26 0.062
Cholesterol (mg/dl) 178.5 ± 3.66 184.25 ± 3.89 182.73 ± 4.16 0.56
HDL‑cholesterol (mg/dl) 46.04 ± 1.11 41.01 ± 1.17 43.42 ± 1.13 0.009
LDL‑cholesterol (mg/dl) 102.34 ± 2.88 113.58 ± 3.63 109.88 ± 3.44 0.051
Triglycerides (mg/dl) 148.73 ± 7.29 143.17 ± 10.81 163.78 ± 12.52 0.38
Systolic blood pressure (mmHg) 137.8 ± 1.5 139.4 ± 2.5 144.2 ± 2.4 0.070
Diastolic blood pressure (mmHg) 80.1 ± 0.91 81.9 ± 1.7 81.6 ± 1.3 0.507
Hospitalization days 4.84 ± 0.31 12.94 ± 1.22 7.32 ± 0.58 <0.0001
Fig. 1 GDF‑15 plasma levels in pg/ml in patients with stable coro‑
nary artery disease (SCAD), ST‑elevation myocardial infarction (STEMI) 
and non‑ST‑elevation myocardial infarction (NSTEMI) (P < 0.0001 for 
STEMI vs. SCAD)
Page 4 of 7Farhan et al. Cardiovasc Diabetol  (2016) 15:60 
GDF-15 was only weakly predictive of the combined 
ischemic endpoint (AUC 0.473, CI 0.387–0.560, P 0.044).
Discussion
The main results of the present study are: first, patients 
with ACS especially those with STEMI show the highest 
GDF-15 levels compared to those with SCAD. Second, 
several factors or conditions are independent determi-
nants of elevated GDF-15 levels in patients with CAD 
who undergo PCI (advanced age, DM, AHG, inflamma-
tion and CKD).
GDF-15 is a member of the transforming growth factor 
ß family [1]. Under healthy conditions GDF-15 is rarely 
expressed [5]. In case of oxidative stress and inflamma-
tion, GDF-15 expression is up-regulated [18, 19]. Sev-
eral parameters and conditions have been introduced as 
inducers of GDF-15 secretion [3, 4, 8, 20–22]. Patients 
with CAD undergoing bypass surgery are at increased risk 
to develop acute kidney injury when their pre-operative 
GDF-15 levels were elevated [23]. In patients with DM, 
GDF-15 predicts worsening of kidney function measured 
by albminuria [3]. Several investigations evidenced a rela-
tion between GDF-15 and markers of metabolic dysfunc-
tion e.g. impaired fasting glucose [8], insulin resistance 
and glucose metabolism [4], obesity [24], inflammation 
[1] and finally aging [25]. Our findings correlate with 
those observations as we found advanced age, DM, obe-
sity (BMI  >25  kg/m2), CRP and CKD were independent 
predictors of elevated GDF-15 in patients with CAD who 
needs PCI. Our investigation extends that knowledge in 
terms of AHG (Table 2). This is to the best of our knowl-
edge a unique finding of the present study. AHG occurs 
in nearly 25  % of patients with ACS without history of 
DM [26, 27]. AHG has been linked to worse outcome 
in patients with ACS [28, 29]. AHG remotes ischemic 
preconditioning in experimental conditions [30]. In an 
in vitro study, hyperglycemia induced GDF-15 expression, 
which resulted in umbilical endothelial cell apoptosis [31]. 
Until today, the reason for elevated glucose levels in the 
setting of ACS is still matter of debate. Our investigation 
support the hypothesis that GDF-15 is linked to chronic 
hyperglycemia in case of DM patients and also to acute 
deteriorations in glucose metabolism reflected by AHG.
GDF-15 is even found in infracted myocardium as well 
as atherosclerotic plaque [5, 18, 19]. However, GDF-15 is 
not a typical marker of myocardial necrosis e.g. troponin 
[6, 7] and could not be used as a marker for detection of 
acute myocardial necrosis [6, 7]. GDF-15 has been intro-
duced as a prognostic marker in patients with ACS espe-
cially those with NSTEMI [6, 7]. Additionally a sub-study 
of the ICTUS trial showed a predictive role for GDF-15 
Fig. 2 Column diagram of cardiovascular death rates among the 
three established thresholds for GDF‑15 plasma levels [6] in patients 
with CAD undergoing PCI. The numbers above the columns are 
expressed as percent (P < 0.0001)
Table 2 Unadjusted and adjusted OR for elevated GDF-15 in patients with CAD undergoing PCI
OR odds ratio, CI confidence interval, ACS acute coronary syndrome, AHG acute hyperglycemia, DM diabetes mellitus, MI myocardial infarction, CKD chronic kidney 
disease, NYHA New York Heart Association, BMI body mass index, CRP high sensitive C-reactive protein
Variable Unadjusted OR and 95th CI P value Adjusted OR and 95th CI P value
Advanced age (>75 years) 10.754 (6.003–19266) <0.0001 8.262 (3.852–17.722) <0.0001
Female gender 1.414 (0.958–2.087) 0.081
ACS diagnosis 1.513 (1.045–2.191) 0.028 0.912 (0.506–1.645) 0.760
AHG in patients with ACS 3.297 (1.567–6.938) 0.002 2.815 (1.070–7.403) 0.036
DM 1.932 (1.286–2.903) 0.002 2.210 (1.222–3.995) 0.009
Previous MI 1.606 (1.060–2.432) 0.025 1.514 (0.806–2.844) 0.197
CKD 12.939 (6.071–27.574) <0.0001 6.846 (2.858–16.400) <0.0001
NYHA ≥2 at presentation 1.984 (1.050–3.746) 0.035 1.647 (0.726–3.739) 0.233
Current smoking 1.930 (1.284–2.901) 0.002 0.903 (0.512–1.595) 0.726
Obesity (BMI >25 kg/m2) 1.606 (1.050–2.455) 0.029 2.184 (1.149–4.149) 0.017
Elevated CRP at admission 1.831 (1.206–2.781) 0.005 2.380 (1.377–4.114) 0.002
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in patients with high risk NSTEMI [5]. In patients with 
STEMI a recent sub-study of the PLATO trial showed 
predictive impact of admission GDF-15 for future spon-
taneous MI and death [32]. A further analysis of the 
PLATO trial evidenced a predictive role for GDF-15 in 
patients with ASC undergoing, but not in those without 
invasive management [33]. Similarly in STEMI patients 
who underwent medical reperfusion therapy, GDF-15 
levels were predictive of worse prognosis [2]. Wollert 
et al. found in a sub-investigation of the GUSTO IV trial 
that GDF-15 was a strong predictor of composite end-
point of death and MI [6]. However in that study the 
predictive power for the combined endpoint was mainly 
driven by the endpoint death and not MI [6]. Similar to 
those investigations, we found GDF-15 measured before 
coronary intervention in patients with CAD in stable and 
acute setting is a powerful predictor for death. However, 
GDF-15 was proven not predictive of combined ischemic 
endpoints of (non-fatal MI, UA, unplanned revasculariza-
tion, ST, TIA and stroke). The main differences occurred 
in our vs. previous investigations could be explained by 
the fact that we investigated CAD patients  in chronic 
as well as acute setting undergoing revascularization 
via PCI (PCI performed in 100  % of the study popula-
tion) compared to earlier studies performed by Wollert 
and Kempf [2, 6] In those investigations patients were 
treated with thrombolytics or in less frequency received 
coronary intervention. Additionally the more recent 
studies from the PLATO investigators [32, 33] reflect 
more current guidelines and standard of care (in-hospital 
PCI and CABG ~61 and 4.5 % respectively).
Fig. 3 Forrest plot of multivariate logistic regression analysis of determinants of elevated GDF‑15 plasma levels in patients with CAD
Fig. 4 Receiver operating curve (ROC) for GDF‑15 and death during a 
mean follow‑up of 188 (177.2–243) days (area under the curve (AUC) 
0.852, CI 0.745–0.960, P < 0.0001)
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Limitations our study has several limitations, which 
should be taken into account while interpreting the 
results. First, this is a single center investigation with 
a relative small sample size. Second, other than previ-
ous investigations we examined a mixed population of 
patients with proven CAD who needed a revasculariza-
tion procedure via stent implantation. Therefore, our 
results should not be extrapolated to those patients 
treated medically, those who needed coronary artery 
bypass grafting as revascularization option and those 
with ACS treated medically only after evidencing no sig-
nificant lumen narrowing of epicardial vessels in the cor-
onary angiography. Finally, investigating the predictive 
value of a marker based on a single time point collection 
(snapshot) in a small patient population should be inter-
preted with caution and should be confirmed in further 
studies with higher sample size.
Conclusion
In patients with CAD undergoing PCI with stent implan-
tation, GDF-15 is determined by advanced age, acute and 
chronic hyperglycemia, inflammation and chronic kidney 
disease. GDF-15 is a valuable predictor of CD-death in a 
population of CAD patients after PCI.
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